Tetratherix Ltd (TTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tetratherix Ltd (TTX) has a cash flow conversion efficiency ratio of -0.186x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.53 Million ≈ $-3.21 Million USD) by net assets (AU$24.37 Million ≈ $17.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Tetratherix Ltd to measure how much of total assets are equity-financed.
Tetratherix Ltd - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Tetratherix Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Tetratherix Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Tetratherix Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tetratherix Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EUWAX Aktiengesellschaft
F:EUX
|
0.005x |
|
Darwin Precisions Corp
TW:6120
|
0.016x |
|
Berry Petroleum Corp
NASDAQ:BRY
|
0.087x |
|
United Orthopedic
TWO:4129
|
0.053x |
|
First National Corp
NASDAQ:FXNC
|
0.045x |
|
Gaon Group Ltd
TA:GAGR
|
0.123x |
|
JAKKS Pacific Inc
NASDAQ:JAKK
|
0.089x |
|
Natac Natural Ingredients, S.A.
MC:NAT
|
0.221x |
Annual Cash Flow Conversion Efficiency for Tetratherix Ltd (2023–2025)
The table below shows the annual cash flow conversion efficiency of Tetratherix Ltd from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see Tetratherix Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$27.25 Million ≈ $19.28 Million |
AU$-2.67 Million ≈ $-1.89 Million |
-0.098x | -125.96% |
| 2024-06-30 | AU$-6.78 Million ≈ $-4.80 Million |
AU$-2.56 Million ≈ $-1.81 Million |
0.378x | +343.15% |
| 2023-06-30 | AU$-4.56 Million ≈ $-3.22 Million |
AU$-388.24K ≈ $-274.70K |
0.085x | -- |
About Tetratherix Ltd
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.